GGrantIndex
Sort

40,608 grants matching prostate cancer

Role of FOXO1 Inactivation in Prostate Tumorigenesis

$347,017
Haojie Huang · Mayo Clinic Rochester · R01 · FY2019 · CA

Targeted Drug Delivery

$346,984
Maurizio Pellecchia · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2013 · CA

Growth Factor Signaling in Prostate Development &Cancer

$346,980
Univ Of Med/Dent Nj-R W Johnson Med Sch · R01 · FY2001 · DK

Spectral CT metal artifact correction

$346,975
Taly Gilat Schmidt · Marquette University · R01 · FY2020 · EB

Nitric Oxide as a Modifier of Oxidative Stress

$346,967
David Wink · Division Of Clinical Sciences - Nci · ZIA · FY2011 · CA

Converting Cold to Hot Tumor Microenvironment in Prostate Cancer by Targeting Chromatin Effector

$346,934
Xin Lu · University Of Notre Dame · R01 · FY2023 · CA

Growth Factor Signaling in Prostate Development &Cancer

$346,860
Univ Of Med/Dent Nj-R W Johnson Med Sch · R01 · FY2002 · DK

Telomeres, telomerase and chemotherapy: Bench to bedside

$346,857
Jessie L.-S. Au · Optimum Therapeutics, Llc · R01 · FY2009 · CA

Discovery of Selective MAP2K4 Inhibitors to Target Metastasis

$346,802
Karl A Scheidt · Northwestern University · R01 · FY2016 · CA

Discovery of Selective MAP2K4 Inhibitors to Target Metastasis

$346,802
Karl A Scheidt · Northwestern University · R01 · FY2015 · CA

Discovery of Selective MAP2K4 Inhibitors to Target Metastasis

$346,802
Karl A Scheidt · Northwestern University · R01 · FY2017 · CA

Cancer and Leukemia Group B: RPCI/SUNYAB

$346,791
Roswell Park Cancer Institute Corp · U10 · FY2003 · CA

Dissecting and targeting a novel vulnerability in aggressive Rb1 and p53 doubly deficient prostate cancer

$346,789
Wenliang Li · University Of Texas Hlth Sci Ctr Houston · R01 · FY2023 · CA

Systematic Genetic Characterization of African American Prostate Cancer

$346,750
Levi Alexander Garraway · Dana-Farber Cancer Inst · U01 · FY2012 · CA

Molecular Determinants of Androgen Receptor Pharmacology

$346,733
Donald P McDonnell · Duke University · R01 · FY2012 · CA

Human Endogenous retroviruses as potential early markers for Alzheimer's disease

$346,716
Farah Bakhshian Rahmatpanah · University Of California-Irvine · R01 · FY2022 · CA

Project 2: Androgen deprivation as an immune modulating therapy in combination with targeted immunotherapy of prostate cancer

$346,701
Douglas G McNeel · University Of Wisconsin-Madison · P50 · FY2023 · CA

Toward Selective Androgen Deprivation by Targeting Androgen Activation of SRF

$346,685
Hannelore Heemers · Cleveland Clinic Lerner Com-Cwru · R01 · FY2022 · CA

Toward Selective Androgen Deprivation by Targeting Androgen Activation of SRF

$346,685
Hannelore Heemers · Cleveland Clinic Lerner Com-Cwru · R01 · FY2023 · CA

Targeting Cell Cycle Alterations to Improve Treatment for Advanced Prostate Cancer

$346,682
Karen E Knudsen · Thomas Jefferson University · R01 · FY2019 · CA

Tissue and Specimen Core

$346,674
Robert Vessella · Fred Hutchinson Cancer Research Center · P50 · FY2008 · CA

Improving chemotherapy of castration-resistant prostate cancer.

$346,655
Xiaoqi Liu · University Of Kentucky · R01 · FY2025 · CA

SPORE IN PROSTATE CANCER

$346,638
University Of Michigan At Ann Arbor · P50 · FY2000 · CA

Phosphorylatable Monoclonal Antibodies for Tumor Therapy

$346,630
Pbl Biomedical Laboratories · R44 · FY2003 · CA

Project 2: Arsenic as an Endocrine Disruptor

$346,603
Joshua W Hamilton · Dartmouth College · P42 · FY2010 · ES